ENTITY
Biogen Inc

Biogen Inc (BIIB US)

142
Analysis
Health Care • United States
Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products address diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis.
more
bearish•Samsung Biologics
•22 Oct 2018 22:52

Samsung BioLogics Update

Recent developments in Samsung Biologics Co., (207940 KS)'s business have been mixed with a negative skew. First, partner Merck & Co Inc (MRK...

Share
bullish•Eisai Co Ltd
•03 Jul 2018 20:11

Merck Alliance Provides Stability to Deal With the Outcome of High Risk Alzheimer’s R&D in FY19

We upgrade Eisai Co Ltd (4523 JP) to “Equal-weight” after reviewing our model post FY17 (YE Mar-18) earnings, in light of the augmented peak sales...

bullish•Samsung Biologics
•30 Jun 2018 07:59

Biogen Exercises Samsung Bioepis Call Option - Summary & Implications

Samsung Biologics Co., Ltd (207940 KS) said in a regulatory filing that Biogen Inc (BIIB US) exercised Bioepis call option. Link of this...

Logo
336 Views
Share
•26 May 2018 07:11

The Week That Was In North Asia@Smartkarma: A Week of Cancellations & Baby Come Back

This past week was one of cancellations, highlighted by Trump cancelling his meeting with Kim Jong-Un and the Hyundai Motor Group cancelling the...

Logo
258 Views
Share
x